Amarin rises as heart drug spotlighted at major cardiology meet

Amarin

08/04/2026 13:57

** Shares of drug developer Amarin AMRN.O rise 2.1% to $15 premarket

** Co says new analyses reinforce benefits of Vascepa, its heart drug used to lower the risk of serious heart events in high‑risk patients

** Icosapent ethyl targets high triglycerides, a type of blood fat that can raise heart attack and stroke risk even when cholesterol is controlled - AMRN

** Co says secondary analysis of its study showed fewer heart‑related events when the drug was added to standard statin therapy in the highest‑risk patients

** Updated U.S. cardiology guidelines flagged high triglycerides as an ongoing heart risk and recommend treatments beyond statins for some patients, while cautioning against routine fibrate use - AMRN

** Drug is sold as Vascepa in the U.S. and Vazkepa in Europe and is approved in nearly 100 markets, co says

** As of last close, stock up ~5% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))